rUTI Resolution After FMT for *Clostridioides difficile* Infection: A Case Report

Andrea Aira · Elisa Rubio · Andrea Vergara Gómez · Csaba Fehér · Climent Casals-Pascual · Begoña González · Laura Morata · Verónica Rico · Alex Soriano

Received: September 24, 2020 / Accepted: October 21, 2020 / Published online: November 2, 2020
© The Author(s) 2020

**ABSTRACT**

*Clostridioides difficile* infection (CDI) is the leading cause of nosocomial infectious diarrhea. Fecal microbiota transplantation (FMT) is a successful treatment for recurrent CDI (rCDI), and in some patients FMT has been associated with the resolution of recurrent urinary tract infections (rUTI). Recent evidence suggests that the origin of most bacterial infections in the urinary tract is the gut. Thus, the possibility of using FMT to displace pathogens commonly involved in rUTIs has major therapeutic implications. We report the case of a 93-year-old female patient with a rCDI and rUTI that underwent FMT and reported a complete clinical resolution of CDI; unexpectedly, no new symptomatic UTI episodes were diagnosed post-FMT. We characterized the gut microbiota of the stool donor and of the patient before and after the procedure. Our patient presented a dysbiosis with clear predominance of Enterobacteriaceae (74%) before FMT, which was significantly reduced to 0.07% after FMT. These findings were maintained for almost a year. We also observed an increase in microbial diversity indices compared with the pre-FMT sample reaching diversity values comparable to the donor stool samples. We reasoned that the disappearance of UTIs in our patient resulted from the reduction of Enterobacteriaceae in the gut microbiota. Our findings support previous evidence suggesting the potential of FMT for rUTI, particularly in cases due to multi-drug resistant pathogens where conventional antibiotic treatment is not an option.

**Keywords:** *Clostridioides difficile* infection; Fecal microbiota transplantation; Recurrent urinary tract infection
**Key Summary Points**

Fecal microbiota transference (FMT) is a successful treatment for recurrent *Clostridioides difficile* infection (rCDI). In some patients FMT has been associated with the resolution of recurrent urinary tract infections (rUTIs).

It has been demonstrated that a high predominance of Enterobacterales in the gut microbiota is associated with rUTIs. Using FMT to reduce this predominance could have a major therapeutic implication.

A 93-year-old female patient with rUTI and rCDI as a consequence of antibiotic treatment underwent FMT and reported a complete clinical resolution post-FMT.

The analysis of gut microbiota showed a marked dysbiosis with a clear predominance of Enterobacterales (74%) before FMT, which was significantly reduced to 0.07% 1 year after FMT.

The microbial diversity indices increased, reaching diversity values comparable to the donor stool samples.

---

**DIGITAL FEATURES**

This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to [https://doi.org/10.6084/m9.figshare.13118507](https://doi.org/10.6084/m9.figshare.13118507).

**INTRODUCTION**

*Clostridioides difficile* infection (CDI) is a frequent cause of antibiotic-associated diarrhea. It is the leading cause of nosocomial infectious diarrhea with an incidence in Europe of 5 episodes for 10,000 days of hospitalization [1]. The number of community-acquired infections is also growing, representing up to 33% of all CDI cases [2]. The main risk factors of CDI are the use of antibiotics (especially fluoroquinolones, cephalosporin, ampicillin and amoxicillin) and age > 65 years [3], but also admission to healthcare facilities, immunosuppression, chemotherapy, inflammatory bowel disease or proton pump inhibitors [1].

Fecal microbiota transplantation (FMT) restores the composition and functionality of the gut microbiota and is approved as a successful treatment for recurrent CDI [4]. Furthermore, it has been shown that FMT reduces the mortality rate in patients with severe CDI that fail to respond to conventional anti-clostridial antibiotic treatment [5, 6]. There are several mechanisms to explain the effectiveness of FMT, including direct competition of donor microbiota with *C. difficile*, restoration of secondary bile acid metabolism and repair of the gut barrier by stimulation of the mucosal immune system [5].

In some cases, FMT has been associated with the resolution of recurrent urinary tract infections (rUTI) in CDI patients who underwent FMT [7, 8]. rUTI in women is mostly associated with being a fecal carrier of specific serotypes of *Escherichia coli* expressing fimbriae that are highly adherent to the urothelium. This circumstance favors the colonization of the urethra and posterior invasion of the bladder, causing cystitis or even pyelonephritis [9]. Recent evidence suggests that the origin of the majority of bacterial infections in the urinary tract is the gut. Thus, the possibility to use FMT to displace pathogens commonly involved in rUTIs such as *Proteobacteria* (including *E. coli*) has major therapeutic implications [10].

Here we report the case of a patient who underwent FMT to treat a recurrent CDI (rCDI) and subsequently reported a complete clinical resolution of recurrent urinary infections. We studied the composition and diversity of the microbial communities of the stool donor and also the gut microbiota of the patient before and 1 year after the FMT.
CASE

The patient was a 93-year-old female with a history of chronic infection by hepatitis C virus, end sigmoid colostomy for acute diverticulitis and rUTI (3 episodes) for 1 year preceding consultation caused by *Escherichia coli* and *Pseudomonas aeruginosa*; both were treated with ciprofloxacin at another institution. As a prophylaxis for rUTI, since the last episode the patient had received ciprofloxacin 250 mg daily for 3 months.

She was admitted to our hospital for severe diarrhea with positive toxin for *C. difficile*, which was treated successfully with oral (po) vancomycin 125 mg/6 h for 14 days and intravenous (iv) tigecycline 50 mg/12 h for 7 days. Four months later, the patient had a recurrent CDI with signs of severity (leukocytosis, high creatinine, hypotension, abdominal pain and metabolic acidosis), and she was treated with oral fidaxomicin 200 mg/12 h for 10 days and iv tigecycline 50 mg/12 h for 5 days. At the end of this regimen, fidaxomicin was maintained every 48 h, but diarrhea, fever and elevated white blood cell count recurred, and FMT was proposed and accepted by the patient and her relatives.

Potential stool donors were screened for potential infectious pathogens following the European recommendations [4]. Donor blood testing included complete blood count, blood chemistry tests, and serology for HIV, herpes simplex virus, Epstein-Barr virus, toxoplasma, HTLV, hepatitis B and C virus, and cytomegalovirus. Donor stools were examined to check for intestinal parasites, *C. difficile* toxin, bacterial culture and presence of multidrug-resistant microorganisms (including ESBLs and carbapenemases). A fresh donor stool was mixed with normal saline and homogenized using a Stomacher 400 Circulator for 1 min at 230 rpm. Then, the stool emulsion was filtered using a sterile strainer. The filtered stool emulsion was kept at 4 °C until its use. Processed samples were directly infused into the gastrointestinal tract of the patient by colonoscopy.

For genomic analysis, fecal samples were collected from the two donors before FMT and from the patient at four time points: before FMT and 2, 16 and 299 days after the procedure. Samples were stored at −80 °C until processing. DNA was extracted using the PureLinkTM Microbiome DNA Purification Kit (Invitrogen). The 16S rRNA gene V3-V4 region was amplified and sequenced on an Illumina MiSeq platform (2 × 300 bp) following the Illumina 16S Metagenomic Sequencing Library Preparation protocol. Diversity metrics, compositional and statistical analyses were performed using QIIME (QIIME 2 version 2020.2) and R version 3.4.4. Taxonomy was assigned using Silva version 132.

Samples with < 1000 sequence reads were removed. Singletons and features with a relative frequency < 0.01% were also removed. Finally, samples were rarefied to 4300 read sequencing depth for alpha diversity and compositional calculations.

From the genomic sequences, the microorganisms that shared > 97% sequence identity were grouped in operational taxonomic units (OTUs) obtaining the number of species in the sample or species richness [11]. For microbial diversity analysis, we used three different diversity indices. The Shannon index considers the number of species and their abundance in the sample and showed the heterogeneity of the microbial community [12]. Evenness was measured to observe differences in the relative abundance of the present species [11]. Finally, the Faith index or phylogenetic diversity evaluated the phylogenetic differences between the species in the sample and gave information on overall diversity [13].

The patient received a FMT by colonoscopy through the colostomy using a solution of 350 ml corresponding to 35 g of homogenate feces as previously described. The donor for the FMT was a healthy relative. The donor stool for the FMT was collected by colonoscopy using a colonoscope. The stool was mixed with normal saline and homogenized using a Stomacher 400 Circulator for 1 min at 230 rpm. Then, the stool emulsion was filtered using a sterile strainer. The filtered stool emulsion was kept at 4 °C until its use. Processed samples were directly infused into the gastrointestinal tract of the patient by colonoscopy.

For genomic analysis, fecal samples were collected from the two donors before FMT and from the patient at four time points: before FMT and 2, 16 and 299 days after the procedure. Samples were stored at −80 °C until processing. DNA was extracted using the PureLinkTM Microbiome DNA Purification Kit (Invitrogen). The 16S rRNA gene V3-V4 region was amplified and sequenced on an Illumina MiSeq platform (2 × 300 bp) following the Illumina 16S Metagenomic Sequencing Library Preparation protocol. Diversity metrics, compositional and statistical analyses were performed using QIIME (QIIME 2 version 2020.2) and R version 3.4.4. Taxonomy was assigned using Silva version 132.
corresponding to 50 g feces. Two weeks after the second FMT, a colonoscopy revealed resolution of pseudomembranes (Fig. 1b). No additional treatment for preventing CDI or UTI was added, and during the following year, the patient had no symptoms of CDI even though she received antibiotic treatment for acute respiratory tract infection once during this period. Unexpectedly, no new symptomatic UTI was diagnosed.

It has been previously reported that Bacteroidetes and Firmicutes are the predominant phyla in the healthy intestinal microbiota [14]. In agreement with these data, the gut microbiota analyses from both donor samples presented very similar taxonomic compositions (Fig. 2) with a predominance of the Bacteroidaceae family (Bacteroidetes phylum) and Lachnospiraceae and Ruminococcaceae families (Firmicutes phylum). Before the FMT, the patient’s gut microbiota showed clear signs of dysbiosis with a marked predominance of Enterobacteriaceae (74.23% relative abundance) and more specifically of *Klebsiella* spp. The stool samples collected 2 and 299 days after the first FMT showed a major reduction of Enterobacteriaceae reaching a relative abundance of 0.07% (Fig. 2, Table 1) and, importantly, an increase in alpha diversity indices comparable to those of the donor stool samples (Table 1).

Informed consent was obtained from the patient to be included in this case report.

**DISCUSSION**

The efficacy of FMT for rCDI has been documented in clinical trials [15] and case series [16]. Our patient was elderly, fragile and exposed to antibiotic therapy because of rUTI and therefore at high risk of rCDI [3, 17] that would not respond to vancomycin nor fidaxomicin. Accordingly, she was a good candidate for FMT, and the response was in line with previous results. The reason for the good outcome could be related to the quality, in terms of diversity, of the transferred microbiota shown in Fig. 2 and Table 1 with a high number of OTUs, high values on the Faith and Shannon indices and low relative abundance of the Enterobacteriaceae family.

The main reason for rCDI in our patient was a history of antibiotic treatment due to rUTI, one of the most common causes of antibiotic consumption in the community [9]. Interestingly, our patient has had no more symptomatic UTIs since the FMT. The same experience was reported in two previous publications, including eight and one patients each [7, 8]. It has been documented in adult monkeys.
that the delivery of amoxicillin into the vagina significantly reduces the colonization resistance to *E. coli* by the intestinal microbiota, favoring its spread to the urethra and finally causing UTI [18]. This experimental study supported the concept that the source of uropathogenic
bacteria is the gut microbiota, while predisposing factors include host characteristics (anatomical alterations, sexual behavior, disruption of the vaginal microbiota) and microbial pathogenicity (pathogenic islands) [19]. However, a recent article demonstrated that a 1% relative abundance of E. coli in the gut is an independent risk factor for UTI caused by this pathogen [10], suggesting that beyond the pathogenicity of a specific bacterial clone, the critical factor favoring rUTI is the relative abundance of this pathogen in the gut microbiota. Our patient had a gut predominance of Enterobacteriaceae (74%), which was significantly reduced to 0.07% after FMT, and this low proportion was maintained for almost a year. We consider it a reasonable interpretation that the disappearance of UTIs in our patient was the consequence of this relative reduction of Enterobacteriaceae in the gut microbiota. Our findings support the accumulating evidence for using FMT as a treatment for rUTI, particularly in cases due to multi-drug resistant pathogens where conventional antibiotic treatment is not an option.

The main limitation of our study is the low number of specimens collected after the FMT. Samples were collected 1 day before, 2 days and 299 days after the FMT. More frequent sampling would have been helpful to better understand the timing of the new microbiota acquisition and their fluctuation over time. On the other hand, the opportunity to evaluate long-term stability of the gut microbiota composition after FMT is of great interest.

CONCLUSIONS

FMT is one of the best alternatives to rCDI, and a few reports, with a low number of cases, suggest that it can be an alternative therapeutic option for rUTI, particularly when multidrug-resistant bacteria are responsible for recurrent infections. This case provides further evidence in favor of the potential benefit of FMT to treat rUTI. The potential benefit of FMT in rUTI should be further evaluated in well-designed randomized control trials.

ACKNOWLEDGEMENTS

We thank the participants of the study. We acknowledge the Infectious Disease, Microbiology and Gastroenterology Departments for their contributions.

Funding. This study has been funded by Instituto de Salud Carlos III through the project “PI/1601023” (Co-funded by European Regional Development Fund “Investing in your future”). No funding or sponsorship was received for the publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures. Alex Soriano has received grants from Pfizer and is part of the speaker’s bureau of Pfizer, MSD, Angelini, Shionogy and Menarini. He has participated in advisory meetings for Pfizer, MSD, Menarini and Shionogy. Alex Soriano is also the Editor-in-Chief of this journal. Andrea Aira, Elisa Rubio, Andrea Vargas Gómez, Csaba Fehér, Climent Casals-Pascual, Begoña Gonzalez, Laura Morata and Verónica Rico have no disclosures.

Compliance with Ethics Guideline. Informed consent was obtained from the patient for being included in this case report.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, then permissions to use the material must be obtained from the rightsholder.
Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Bouza E. Consequences of Clostridium difficile infection: Understanding the healthcare burden. Clin Microbiol Infect. 2012;18:5–12.

2. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89–95.

3. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539–48.

4. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–80.

5. Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol. 2016;13:508–16.

6. Hocquart M, Lagier JC, Cassir N, Saidani N, Eldin C, Kerbaj J, et al. Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis. 2018;66:645–50.

7. Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal microbiota transplantation for recurrent Clostridium difficile infection reduces recurrent urinary tract infection frequency. Clin Infect Dis. 2017;65:1745–7.

8. Biehl LM, Cruz Aguilar R, Farowski F, Hahn W, Nowag A, Wisplinghoff H, et al. Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection. Infection. 2018;46:871–4.

9. Glover M, Moreira CG, Sperandio V, Zimmern P. Recurrent urinary tract infections in healthy and nonpregnant women. Urol Sci. 2014;25:1–8.

10. Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10:1–9.

11. Young VB, Schmidt TM. Overview of the gastrointestinal microbiota. In: GI microbiota and regulation of the immune system. New York: Springer; 2008. p. 29–40.

12. Shannon CE. A Mathematical theory of communication. Bell Syst Tech J. 1948;27:379–423.

13. Faith DP. Conservation evaluation and phylogenetic diversity. Biol Conserv. 1992;61:1–10.

14. Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober Ol, Juge N, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Heal Dis. 2015;26:1–17.

15. Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017;207:166–72.

16. van Beurden YH, Nieuwdorp M, van de Berg PJEJ, Mulder CJJ, Goorhuis A. Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation. Ther Adv Gastroenterol. 2017;10:373–81.

17. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58:403–10.

18. Winberg J, Herhelius-Elman M, Möllby R, Nord CE. Pathogenesis of urinary tract infection - experimental studies of vaginal resistance to colonization. Pediatr Nephrol. 1993;7:509–14.

19. Marrs CF, Zhang L, Foxman B. Escherichia coli mediated urinary tract infections: are there distinct uropathogenic E. coli (UPEC) pathotypes? FEMS Microbiol Lett. 2005;252:183–90.